MA28779B1 - Variants d'aprotinine ameliores - Google Patents

Variants d'aprotinine ameliores

Info

Publication number
MA28779B1
MA28779B1 MA29646A MA29646A MA28779B1 MA 28779 B1 MA28779 B1 MA 28779B1 MA 29646 A MA29646 A MA 29646A MA 29646 A MA29646 A MA 29646A MA 28779 B1 MA28779 B1 MA 28779B1
Authority
MA
Morocco
Prior art keywords
aprotinine
variants
improved
proteins
field
Prior art date
Application number
MA29646A
Other languages
English (en)
Inventor
Kevin Lumb
Stanley Horton
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28779B1 publication Critical patent/MA28779B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte au domaine des protéines qui inhibent l'activité de la serine protéase. L'invention se rapporte également au domaine des constructions d'acide nucléique, aux vecteurs et aux cellules hôtes pour la production des protéines inhibitrices de la serine protéase, à des compositions pharmaceutiques contenant de telles protéines, et aux méthodes de leur utilisation.
MA29646A 2004-07-13 2007-02-01 Variants d'aprotinine ameliores MA28779B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58765504P 2004-07-13 2004-07-13

Publications (1)

Publication Number Publication Date
MA28779B1 true MA28779B1 (fr) 2007-08-01

Family

ID=35839810

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29646A MA28779B1 (fr) 2004-07-13 2007-02-01 Variants d'aprotinine ameliores

Country Status (15)

Country Link
US (1) US20090005297A1 (fr)
EP (1) EP1771464A4 (fr)
JP (1) JP2008506391A (fr)
KR (1) KR20070041749A (fr)
CN (1) CN101014611A (fr)
AU (1) AU2005271708A1 (fr)
BR (1) BRPI0513267A (fr)
CA (1) CA2573368A1 (fr)
EC (1) ECSP077240A (fr)
IL (1) IL180370A0 (fr)
MA (1) MA28779B1 (fr)
MX (1) MX2007000473A (fr)
NO (1) NO20070640L (fr)
RU (1) RU2007105137A (fr)
WO (1) WO2006017355A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110301A1 (fr) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Variants d'aprotinine à propriétés améliorées
WO2009030464A2 (fr) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft Préparation et utilisation de variantes d'inhibiteurs de protéase du type kunitz humains (hktpi)
CN101412995B (zh) * 2007-10-17 2011-04-06 江苏正大天晴药业股份有限公司 聚乙二醇修饰的抑肽酶及其制备方法
WO2010033226A1 (fr) * 2008-09-17 2010-03-25 Nektar Therapeutics Conjugués inhibiteurs de protéase-oligomère
WO2010088547A1 (fr) * 2009-01-29 2010-08-05 Bayer Healthcare Llc Dosages de détection de facteurs de coagulation sanguine pégylés
DE102011013326A1 (de) 2011-03-08 2012-09-13 Solution Shop Ag Neue Fibrinolyse-Inhibitoren und deren mdizinische Verwendung
PT2822575T (pt) * 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US9605057B1 (en) * 2013-06-17 2017-03-28 Board Of Regents Of The University Of Texas System Endotrophin neutralization and use thereof
WO2017098516A1 (fr) * 2015-12-10 2017-06-15 The National Institute for Biotechnology in the Negev Ltd. Variantes du domaine inhibiteur du précurseur de la bêta-protéine amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1581692A (en) * 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
RU2007105137A (ru) 2008-08-20
EP1771464A2 (fr) 2007-04-11
NO20070640L (no) 2007-04-11
CA2573368A1 (fr) 2006-02-16
WO2006017355A3 (fr) 2006-12-14
IL180370A0 (en) 2007-06-03
KR20070041749A (ko) 2007-04-19
ECSP077240A (es) 2007-03-29
WO2006017355A2 (fr) 2006-02-16
US20090005297A1 (en) 2009-01-01
CN101014611A (zh) 2007-08-08
AU2005271708A1 (en) 2006-02-16
BRPI0513267A (pt) 2008-05-06
EP1771464A4 (fr) 2008-09-03
JP2008506391A (ja) 2008-03-06
MX2007000473A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
MA28779B1 (fr) Variants d'aprotinine ameliores
PT966465E (pt) Inibidores do enzima imfdh
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EA200100992A1 (ru) Ингибиторы фермента impdh
BR0014516A (pt) Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
WO2006017836A3 (fr) Nouveaux derives de 2-amino-quinazoline utiles en tant qu'inhibiteurs de la $g(b)-secretase (bace)
DE602004014170D1 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
WO2007092854A3 (fr) DÉRIVÉS DE 2-AMINO-QUINOLÉINE UTILES COMME INHIBITEURS DE LA β-SÉCRÉTASE (BACE)
EP1751282A4 (fr) Production de cellules hotes contenant de multiples vecteurs d'integration par transduction serielle
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE502036T1 (de) Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4- düpyrimidinderivate
Horiuchi et al. Ectodomain shedding of FLT3 ligand is mediated by TNF-α converting enzyme
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
EA200800357A1 (ru) Новые фармацевтические соединения
DE60101224D1 (de) Hydroxamsäure derivate
WO2007058862A3 (fr) Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
WO2010054042A3 (fr) Modulateurs diméthylphenoxy de l'activité des protéases virales et/ou de l'activité des enzymes parasitaires
MA47657B2 (fr) Compositions et méthodes pour l'internalisation d'enzymes